Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least primarily educated.~* Accord with Probable Alzheimer disease of National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association(NINCDS-ADRDA)'s Criteria.~* 10 points ≤ Minimum Mean-Square Error(MMSE) ≤ 24 points.~* Hachinski ischemia scale \<4 points.~* Hamilton depression scale ≤10 points.~* Should have stable accompanying person, or at least contact 2 hours per day, 4 days per week with accompanying person. The accompanying person should help the patient throughout the trial.~* Signed the information consent form.~Exclusion Criteria:~* Have been in other clinical trials within 30 days before this trial' start.~* women during pregnancy or lactation.~* Dementia caused by other diseases.~* previous nervous system diseases.~* Abnormal laboratory results.~* Uncontrolled hypertension.~* Unstable or serious diseases of heart, lung, liver, kidney and blood.~* Visual or auditory handicap.~* Significant focal lesions revealed by electronic computer X-ray tomography(CT) or magnetic resonance imaging(MRI) in one year before enrollment.~* Alcohol abuse or drug abuse.~* psychotic, including patients with serious depression.~* Patients being in drug therapy of Alzheimer disease which cannot be stopped.~* In treatment of heparin, Polysaccharide sulfate, mannose ester 3 weeks before the recruitment.~* Investigator consider the patient cannot finish this trial for any reason.~* Relatives or employees of the investigators, staff of the investigate centers, contract research organization and sponsor.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- sodium oligo-mannurarate 900mg (Type: EXPERIMENTAL): None
- sodium oligo-mannurarate 600mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).